Immatics (IMTX) Projected to Post Earnings on Thursday

Immatics (NASDAQ:IMTX) is projected to announce its earnings results before the market opens on Thursday, March 20th. Analysts expect the company to announce earnings of ($0.03) per share and revenue of $16.16 million for the quarter.

Immatics Stock Up 2.2 %

Shares of Immatics stock opened at $4.55 on Thursday. The company has a market cap of $543.07 million, a PE ratio of -6.89 and a beta of 0.83. The business has a 50 day moving average of $5.35 and a 200 day moving average of $8.00. Immatics has a 52 week low of $4.06 and a 52 week high of $13.77.

Institutional Investors Weigh In On Immatics

A hedge fund recently raised its stake in Immatics stock. Bank of America Corp DE raised its stake in Immatics (NASDAQ:IMTX) by 166.0% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 3,575 shares of the company’s stock after acquiring an additional 2,231 shares during the period. Bank of America Corp DE’s holdings in Immatics were worth $25,000 as of its most recent SEC filing. 64.41% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of equities analysts recently commented on IMTX shares. Bank of America decreased their target price on Immatics from $16.00 to $15.00 and set a “buy” rating for the company in a report on Tuesday, November 19th. The Goldman Sachs Group upgraded Immatics to a “strong-buy” rating in a report on Monday, November 25th. Four investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Buy” and an average price target of $16.67.

About Immatics

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics.